

From Response to Resilience: Sustaining Vigilance after Ethiopia's first Marburg Virus Disease Outbreak

Awoke Derbie^{1*}, Daniel Mekonnen¹, Aschalew Gelaw²

¹Department of Medical Microbiology, Bahir Dar University, Bahir Dar, Ethiopia

²Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

Correspondence: awoke.derbie@bdu.edu.et / lawokederbie1@gmail.com

EDITORIAL

The recent outbreak of Marburg virus disease (MVD) in southern Ethiopia marks a critical milestone in the country's public health history, confirming the persistent threat of filoviruses in the region (1). Reported by the Ministry of Health in November 2025, the outbreak centered in the Jinka, Malle, and Dasenech districts, resulting in 14 laboratory-confirmed cases and a high case fatality rate of 64.3%. On 26 January 2026, Ethiopia officially declared the end of the outbreak following two consecutive incubation periods (42 days) without new cases and completion of safe and dignified burial procedures for the last confirmed patient. During the response, approximately 3,800 laboratory tests were conducted, and 857 contacts were identified and monitored. Ethiopia has since entered a 90-day enhanced surveillance phase to ensure early detection of any resurgence (2,3). This outbreak, although successfully contained, confirms the presence of ecological and epidemiological conditions favorable for *filovirus* transmission and underscores the importance of sustained preparedness (4).

Marburg virus is an enveloped, filamentous, negative-sense, single-stranded RNA virus (5) belonging to the family *Filoviridae* and genus *Marburgvirus*. It causes severe viral hemorrhagic fever characterized by the abrupt onset of fever, headache, myalgia, and gastrointestinal symptoms, followed by hemorrhage, shock, and multi-organ dysfunction in severe cases (6–9). The incubation period ranges from 2 to 21 days. Fatal outcomes typically occur within 8–9 days after symptom onset due to systemic viral replication, immune dysregulation, vascular damage, and multi-organ failure (8–10).

MVD is a severe zoonotic viral hemorrhagic fever caused by the Marburg virus, primarily hosted by the Egyptian fruit bat (*Rousettus aegyptiacus*) (11–13). Transmission to humans occurs through exposure to bat-inhabited caves or direct contact with infected bodily fluids (6, 8). Since its first identification in 1967 in Germany (Marburg and Frankfurt) and Serbia (7–9), MVD outbreaks have occurred sporadically across Africa, including Angola, Uganda, Ghana, Tanzania, Rwanda, and Equatorial Guinea (6, 8). Previous outbreaks across Africa have demonstrated the high fatality of the disease, with case fatality rates (CFR) ranging from 20% to 90% (6–8, 14). Ethiopian outbreak (2025–2026) represents a documented expansion of filovirus risk zones, particularly in areas like the Omo Valley, where cave ecosystems support significant bat populations. With no licensed antivirals or vaccines currently available, management remains strictly supportive, making early diagnosis via RT-PCR and rapid isolation the only effective

Article History: Received: November 20, 2025

Revised: December 12, 2025

Accepted: December 20, 2025

Copyright: © 2025 by the authors. This is an open-access article distributed under the terms of [the Creative Commons Attribution-Non-Commercial 4.0 \(CC BY NC 4.0\) International License](https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited, appropriate credit is given, any changes made are indicated, and the use is non-commercial.

Citation: Awoke D, Daniel M, Aschalew G. From Response to Resilience: Sustaining Vigilance after Ethiopia's first Marburg Virus Disease Outbreak. *Ethiop J Health Biomed Sci.* 2025; 15(2): 1-3. <https://doi.org/10.20372/ejhbs.1188>

tools for survival and containment (1, 15-17).

The successful response demonstrated Ethiopia's coordinated national capacity; however, the transition from reactive response to long-term resilience is essential. To mitigate the risk of future spillovers, Ethiopia must prioritize the decentralization of molecular diagnostic capacity to regional laboratories and establish ecological surveillance of bat reservoirs. Institutionalizing rapid response teams and strengthening cross-border collaboration under a One Health framework, integrating human, animal, and environmental health, will be vital.

Furthermore, regulatory preparedness for the emergency use of investigational therapeutics must be established to ensure rapid deployment during future resurgences. The 2025–2026 outbreak should serve as a catalyst for strengthening national health security. By sustaining vigilance and enhancing diagnostic and surveillance infrastructure, Ethiopia can ensure that this first encounter with MVD serves as a foundation for a more resilient public health future.

Competing Interest: The authors declare that they have no competing interests.

Funding: The authors received no specific funding for this work.

Acknowledgments: The authors would like to thank Bahir Dar University for the encouragement we received to do this work. We would also like to thank Dr. Tadesse Belayneh for his professional input and guidance.

REFERENCES

1. Africa CDC. Statement on Confirmed Marburg Virus Disease in Jinka, Southern Region, Ethiopia [Internet]. 2025 [cited 2026 Jan 30]. Available from: <https://africacdc.org/news-item/africa-cdc-statement-on-confirmed-marburg-virus-disease-in-jinka-southern-region-ethiopia/>.
2. World Health Organization. Marburg virus disease - Ethiopia [Internet]. 2026 [cited 2026 Jan 30]. Available from: <https://www.afro.who.int/countries/ethiopia/news/ethiopia-declares-end-first-ever-marburg-virus-disease-outbreak>.
3. Federal Democratic Republic of Ethiopia MoH. Ethiopia Has Succeeded in Controlling Marburg Virus Disease [Internet]. 2026 [cited 2026 Feb 5]. Available from: <https://www.moh.gov.et/marburg-response>.
4. Zhu W, Liu G, Cao W, He S, Leung A, Ströher U, et al. A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease. *Vaccines*. 2022;10(7).
5. Feldmann H, Mühlberger E, Randolph A, Will C, Kiley MP, Sanchez A, et al. Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. *Virus Research*. 1992;24(1):1-19.
6. Srivastava S, Sharma D, Kumar S, Sharma A, Rijal R, Asija A, et al. Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges. 2023; Volume 14 - 2023.
7. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. *Clinical Microbiology and Infection*. 2011;17(7):964-76.
8. World Health Organization. Marburg virus disease [Internet]. 2025 [cited 2025]. Available from: <https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease>.
9. Ristanović Elizabeta S, Kokoškov Nenad S, Crozier I, Kuhn Jens H, Gligić Ana S. A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967. *Microbiology and Molecular Biology Reviews*. 2020;84(2):10.1128/membr.00095-19.
10. Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. *Future virology*. 2011;6(9):1091-106.
11. Towner JS, Amman BR, Sealy TK, Carroll SAR, Comer JA, Kemp A, et al. Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats. *PLOS Pathogens*. 2009;5(7):e1000536.
12. Schuh AJ, Amman BR, Guito JC, Graziano JC, Sealy TK, Towner JS. Modeling natural coinfection in a bat reservoir shows modulation of Marburg virus shedding and spillover potential. *PLOS Pathogens*. 2025;21(3):e1012901.

13. Amman BR, Carroll SA, Reed ZD, Sealy TK, Balinandi S, Swanepoel R, et al. Seasonal pulses of Marburg virus circulation in juvenile *Rousettus aegyptiacus* bats coincide with periods of increased risk of human infection. *PLoS Pathog.* 2012;8(10):e1002877.
14. US Centers for Disease Control and Prevention. History of Marburg Outbreaks [Internet]. 2025 [cited 2025]. Available from: https://www.cdc.gov/marburg/outbreaks/index.html#cdc_listing_add_info-references.
15. World Health Organization. Ebola and Marburg disease outbreaks: infection prevention and control research priorities in health care settings [Internet]. 2024 [cited 2025]. Available from: <https://www.who.int/publications/i/item/9789240098381>.
16. Aceng JR, Ario AR, Muruta AN, Makumbi I, Nanyunja M, Komakech I, et al. Uganda's experience in Ebola virus disease outbreak preparedness, 2018–2019. *Globalization and Health.* 2020;16(1):24.
17. Africa CDC A. Lessons Learnt from the Marburg Virus Disease (MVD) Outbreak in Tanzania [Internet]. 2023 [cited 2025 Jan]. Available from: <https://africacdc.org/news-item/lessons-learnt-from-the-marburg-virus-disease-mvd-outbreak-in-tanzania/>.